Targeting castration-resistant prostate cancer with a novel ROR
Acta Pharmaceutica Sinica B
;
(6): 2313-2322, 2020.
Article
in English
| WPRIM
| ID: wpr-881113
ABSTRACT
Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor ROR
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Acta Pharmaceutica Sinica B
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS